Expand Medicare beneficiaries' access to more affordable prescription drugs.

Doris O. Matsui · California · Democratic

policy impact 3.00 specificity 4.00 extraction confidence 99%

Contest this claim

Occurrences

introduced the Ensuring Access to Lower-Cost Medicines for Seniors Act, bipartisan legislation to expand Medicare beneficiaries’ access to more affordable prescription drugs

Introduces legislation aimed at lowering seniors' prescription drug costs.

Press Releases | Congresswoman Doris Matsui
primary · press_release · model gpt-5.4-mini

Evidence

Ms. Matsui (for herself, Mrs. Miller-Meeks, and Mr. Auchincloss) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means... This Act may be cited as the “Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.”

Matsui introduced a bill to require Medicare Part D formularies to include certain lower-cost generic drugs and biosimilars, with referral to Energy and Commerce and Ways and Means. This is a concrete legislative effort toward the claim, but it is only introduction and referral, not enactment or implementation.

unresolved same_term A for effort

H.R. 8143 (IH) - Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026. - BILLS-119hr8143ih | Content Details | GovInfo
secondary · model gpt-5.4-mini · confidence 95%

Contest this evidence item

Assessments

delivered same_term

The promised outcome was broadly achieved at the federal level through enacted Medicare prescription drug reforms in the Inflation Reduction Act of 2022, including Medicare drug price negotiation authority, insulin cost caps, vaccine cost-sharing elimination, inflation rebates, and a Part D out-of-pocket cap. Matsui was a sitting House Democrat when the Act passed the House on August 12, 2022 and was signed into law on August 16, 2022, so her vote materially advanced an enacted federal outcome in office. Her 2026 bill to require Part D formularies to include certain lower-cost generics and biosimilars is additional same-term effort, but delivery does not depend on that pending bill.

provider codex_cli · model gpt-5.5 · confidence 82%